Ischemia reperfusion injury (IRI), also known as reoxygenation injury, is tissue damage that occurs when blood supply to the tissue is restored (reperfusion) after a period of oxygen deprivation (ischemia). Ischemia damage can cause bradycardia, cerebral discomfort, hypertension, and convulsions, among other symptoms.
Market Dynamics
The rise in the number of tissue damage cases and growing awareness of the treatment of reperfusion injury are two major factors driving the growth of the global ischemia reperfusion therapies market. Furthermore, the introduction of novel drugs for the therapy of ischemia reperfusion-related confusions, as well as increased examination and improvement exercises, are driving market growth. Faraday Pharmaceuticals, for example, announced promising top-line findings from the stage II preliminary of FDY-5301 for ischemia reperfusion damage therapies treatment in November 2019.
The COVID-19 pandemic has had an impact on the global ischemia reperfusion injury therapeutics market, as it has become difficult to direct research in the flow situation. As a result, a few market companies are focusing on strategies that can help patients with ischemia reperfusion injury maintain coordination during medical treatment interruptions. In addition, a few government organisations around the world are developing plans and recommendations to deal with the current crisis.
Read More: https://bit.ly/3F5avdZ
